Gilead to License Hepatitis C Drug to Lower-Cost Manufacturers in India

Published February 13, 2014

Gilead to license hepatitis C drug to lower-cost manufacturers in India
In the United States, where Sovaldi was approved by regulators in December, the drug costs $ 84,000 for 12 weeks of therapy or $ 1,000 for a daily pill. The Foster City, California-based company has said the price is fair because the treatment offers a …
Read more on Firstpost

Hepatitis C patient can't access costly new drugs without private insurance
The new drugs, which cost upwards of $ 100,000 for a 12-week treatment, would likely cure her. But they haven't yet been approved for coverage by the Ontario Drug Benefit (ODB) program, which pays most of the cost of hepatitis C treatments for eligible …
Read more on Ottawa Citizen

More Cost Of Drug Treatment Information…